News

Mutations in the C9orf72 gene are the most common genetic cause leading to amyotrophic lateral sclerosis (ALS). Despite this, researchers have not been able to determine what the normal function of the gene really is. Now, scientists from Cedars-Sinai Medical Center in Los Angeles have revealed that the gene contributes to…

Eisai announced it has withdrawn its new drug application for an ultra-high dose Mecobalamin as a treatment for amyotrophic lateral sclerosis (ALS) in Japan, and is reviewing its next steps in consultation with Japanese regulatory officials. Mecobalamin is one of the co-enzyme forms of vitamin B12. As it is physiologically equivalent…

Scientists from Rutgers and Stanford universities have developed a potentially revolutionary technique to grow new neurons from adult stem cells and better ensure their survival during transplantation to the brain. The method, involving the use of 3-D scaffolds, may one day help to treat amyotrophic lateral sclerosis (ALS). Published in the…

When the New York State Department of Health‘s Medical Marijuana Program was launched on Jan. 7, 2016, Upper East Side physician Dr. Thomas O’Brien was the first doctor to secure a certification for a patient to be prescribed medical marijuana. He has since helped 200 patients to achieve…

The ALS Association has announced the five winners of its Translational Research Advancing Therapy for ALS (TREAT ALS) grant awards, advancing research projects into improved treatments and, eventually, a cure for amyotrophic lateral sclerosis. There are two types of grants — TREAT ALS Drug Development Contract and ALS Association-Initiated — which total more…

Six people will run for the UMass ALS Cellucci Fund in this year’s edition of the Boston Marathon, raising awareness and money for amyotrophic lateral sclerosis (ALS) research underway at UMass Medical School (UMMS). For Chris Benyo, the Boston Marathon is like no other. When he crosses the starting line on April 18, Benyo will be…

“The ALS Assistive Technology Challenge, a joint initiative by The ALS Association and Prize4Life is offering a $400,000 prize for the development of flexible, accessible technology to help people with ALS communicate with ease. The challenge is open to academics, industry, start-ups and anyone who believes they can…

Researchers at The Scripps Research Institute discovered that cells instruct proteins to form aggregates to protect them from toxicity associated with neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The research team, led by Claudio Joazeiro, associate professor of cell and molecular biology at Scripps, identified an enzyme that…

Scripps Research Institute (TSRI) scientists have identified a new player in the ribosome-associated quality control complex that “tags” abnormal proteins, prompting them to aggregate and form clumps. This study, for a first time, shows that proteins can be marked for aggregation, and may constitute a new molecular pathway underlying neurodegenerative diseases such…

The ALS Association, together with partner Prize4Life, has announced the First Phase winners of The ALS Assistive Technology Challenge, which now enters its Prize Phase, where $400,000 will be awarded for the development of flexible, accessible technology to help people with amyotrophic lateral sclerosis (ALS) communicate better.